keyword
https://read.qxmd.com/read/38020309/inhibition-of-cancer-cell%C3%A2-platelet-adhesion-as-a-promising-therapeutic-target-for-preventing-peritoneal-dissemination-of-gastric-cancer
#21
JOURNAL ARTICLE
Takashi Nakayama, Ryo Saito, Shinji Furuya, Katsutoshi Shoda, Suguru Maruyma, Koichi Takiguchi, Kensuke Shiraishi, Hidenori Akaike, Yoshihiko Kawaguchi, Hidetake Amemiya, Hiromichi Kawaida, Nagaharu Tsukiji, Toshiaki Shirai, Hideyuki Shinmori, Masami Yamamoto, Sachiyo Nomura, Tetsuya Tsukamoto, Katsue Suzuki-Inoue, Daisuke Ichikawa
Platelets form complexes with gastric cancer (GC) cells via direct contact, enhancing their malignant behavior. In the present study, the molecules responsible for GC cell-platelet interactions were examined and their therapeutic application in inhibiting the peritoneal dissemination of GC was investigated. First, the inhibitory effects of various candidate surface molecules were investigated on platelets and GC cells, such as C-type lectin-like receptor 2 (CLEC-2), glycoprotein VI (GPVI) and integrin αIIbβ3, in the platelet-induced enhancement of GC cell malignant potential...
December 2023: Oncology Letters
https://read.qxmd.com/read/37996643/characterizing-the-immune-environment-in-peritoneal-carcinomatosis-insights-for-novel-immunotherapy-strategies
#22
JOURNAL ARTICLE
Patrick L Wagner, Chelsea M Knotts, Vera S Donneberg, Neda Dadgar, Christian Cruz Pico, Kunhong Xiao, Ali Zaidi, Suzanne C Schiffman, Casey J Allen, Albert D Donnenberg, David L Bartlett
BACKGROUND OR PURPOSE: Carcinomatosis, a distinct pattern of metastatic cancer in the peritoneal cavity, poses challenges for treatment and has limited therapeutic options. Understanding the immune environment of peritoneal surface malignancies is crucial for developing effective immunotherapeutic approaches. This study characterizes soluble immune mediators in the peritoneal fluid of patients with and without carcinomatosis to identify targets for novel treatment strategies. PATIENTS AND METHODS: Serum and peritoneal fluid samples were collected from surgical patients, and a multianalyte analysis was performed using the Luminex platform...
November 23, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/37994292/long-term-survival-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-waikato-aotearoa-new-zealand-a-12-year-experience
#23
JOURNAL ARTICLE
Rennie Xinrui Qin, Jia Hui Lim, Jasen Ly, Jesse Fischer, Nicholas Smith, Mosese Karalus, Linus Wu, Roelef van Dalen, Simione Lolohea
BACKGROUNDS: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have improved survival for selected cases of peritoneal surface malignancy. In 2008, a CRS/HIPEC service was first established in Aotearoa New Zealand (AoNZ) at Waikato and Braemar Hospitals in the Waikato region. METHODS: This is a retrospective review of a prospectively maintained database of all patients undergoing CRS/HIPEC from 1 January 2008 to 1 November 2020 at Waikato and Braemar Hospitals...
November 22, 2023: ANZ Journal of Surgery
https://read.qxmd.com/read/37980712/aso-visual-abstract-cost-analysis-and-financial-implications-of-a-peritoneal-surface-malignancy-program-in-the-united-states
#24
JOURNAL ARTICLE
Andres A Abreu, Emile Farah, Robert Nix, Dustin Kethley, Collin Coble, Zhihan Wan, Rodrigo E Alterio, Fallon Ngo, Anupama Wadhwa, Georgios Karagkounis, Javier Salgado Pogacnik, Sam C Wang, Mathew Augustine, Adam C Yopp, Herbert J Zeh, Patricio M Polanco
No abstract text is available yet for this article.
November 19, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/37980705/aso-author-reflections-decoding-the-complexities-of-cytoreductive-surgery-and-hipec-procedural-billing-a-potential-blueprint-for-the-peritoneal-surface-malignancy-surgeon
#25
JOURNAL ARTICLE
Andres A Abreu, Sam C Wang, Giorgios Karagkounis, Patricio M Polanco
No abstract text is available yet for this article.
November 19, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/37940803/2022-peritoneal-surface-oncology-group-international-consensus-on-hipec-regimens-for-peritoneal-malignancies-colorectal-cancer
#26
JOURNAL ARTICLE
Martin Hübner, Kurt van Der Speeten, Kim Govaerts, Ignace de Hingh, Laurent Villeneuve, Shigeki Kusamura, Olivier Glehen
BACKGROUND: Selected patients with peritoneal metastases of colorectal cancer (PM-CRC) can benefit from potentially curative cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC), with a median overall survival (OS) of more than 40 months. OBJECTIVE: The aims of this evidence-based consensus were to define the indications for HIPEC, to select the preferred HIPEC regimens, and to define research priorities regarding the use of HIPEC for PM-CRC...
November 8, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/37903950/cost-analysis-and-financial-implications-of-a-peritoneal-surface-malignancy-program-in-the-usa
#27
JOURNAL ARTICLE
Andres A Abreu, Emile Farah, Robert Nix, Dustin Kethley, Collin Coble, Zhihan Wan, Rodrigo E Alterio, Fallon Ngo, Anupama Wadhwa, Georgios Karagkounis, Javier Salgado Pogacnik, Sam C Wang, Mathew Augustine, Adam C Yopp, Herbert J Zeh, Patricio M Polanco
BACKGROUND: We aimed to describe the financial implications of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in the USA. MATERIALS AND METHODS: We conducted a retrospective cost analysis of 100 CRS/HIPEC procedures to examine the impact of patient and procedural factors on hospital costs and reimbursement. A comparison of surgeons' work relative value units (wRVUs) between CRS/HIPEC and a representative sample of complex surgical oncology procedures was made to assess the physicians' compensation rate...
January 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/37768120/-surgery-of-peritoneal-surface-malignancies-surgical-cytoreduction-and-hyperthermic-intraperitoneal-chemotherapy
#28
JOURNAL ARTICLE
Gergely Huszty, László Bihari, László Gráf, Attila Szijártó, Szabolcs Máté
Peritoneal carcinosis has historically been considered as inoperable, although the technique of its resesection together with high dose intraperitoneal chemotherapy potentiated by heat has been described decades ago. It has not became a widely practiced routine except in specialized centers - the complex technique, weakly standardized but resource demanding chemotherapy, lacking financial background and the many times questionable clinical benefit at a cost of high surgical load might have been the key factors...
September 28, 2023: Magyar Onkologia
https://read.qxmd.com/read/37762490/anti-tumor-immunogenicity-of-the-oncolytic-virus-cf33-hnis-antipdl1-against-ex-vivo-peritoneal-cells-from-gastric-cancer-patients
#29
JOURNAL ARTICLE
Zhifang Zhang, Annie Yang, Shyambabu Chaurasiya, Anthony K Park, Sang-In Kim, Jianming Lu, Hannah Valencia, Yuman Fong, Yanghee Woo
We studied the immunotherapeutic potential of CF33-hNIS-antiPDL1 oncolytic virus (OV) against gastric cancer with peritoneal metastasis (GCPM). We collected fresh malignant ascites (MA) or peritoneal washings (PW) during routine paracenteses and diagnostic laparoscopies from GC patients (n = 27). Cells were analyzed for cancer cell markers and T cells, or treated with PBS, CF33-GFP, or CF33-hNIS-antiPDL1 (MOI = 3). We analyzed infectivity, replication, cytotoxicity, CD107α upregulation of CD8+ and CD4+ T cells, CD274 (PD-L1) blockade of cancer cells by virus-encoded anti-PD-L1 scFv, and the release of growth factors and cytokines...
September 16, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37727202/brain-metastases-with-malignant-peritoneal-mesothelioma-never-reported-before
#30
Darshan Lal, Merissa Misiura, Waqas Adeel, Rizwan Tariq
Malignant mesothelioma is a very rare diagnosis. Malignant mesotheliomas arise from surface linings of pleura, peritoneal cavity, or tunica vaginalis and pericardium with pleural malignant mesotheliomas being the most common. The incidence of brain metastases has been very low with malignant pleural mesotheliomas, but to date, there have not been any cases reported of brain metastasis with malignant peritoneal mesotheliomas. We present a patient diagnosed with malignant peritoneal mesothelioma and was successfully treated with immunotherapy for over two years but later presented with brain metastases...
August 2023: Curēus
https://read.qxmd.com/read/37710921/endometrial-stromal-sarcoma-with-cardiac-metastasis
#31
Sema Turker, Deniz Suha Kucukaksu, Vedat Bakuy, Saime Ramadan, Ozlem Yenidunya
Cardiac metastases are the most common cardiac tumours. Any malignant tumour can metastasise to heart, but the most common causes of cardiac metastases are melanoma, lung, breast, oesophageal, and haematological malignancies. Endometrial stromal sarcoma (ESS) is a very rare endometrial malignancy. Metastases are usually found in the abdominal cavity, particularly on the peritoneal surfaces. Rarely, metastases to distant organs have also been reported. Cardiac metastases of ESS are extremely rare. Herein, we present a case of ESS who underwent successful surgery for right atrial metastasis 23 months after the initial diagnosis...
January 2023: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://read.qxmd.com/read/37679494/epidemiology-of-psychiatric-disorders-following-cytoreductive-surgeries-plus-hyperthermic-intraperitoneal-chemotherapy-a-prospective-cohort-analysis
#32
JOURNAL ARTICLE
Guillaume Economos, Vahan Kepenekian, Cécile Barbaret, Laurent Villeneuve, Julie Haesebaert, Olivier Glehen
The peritoneal surface malignancy (PSM) is an advanced disease, the prognosis of which has been radically improved since the development of cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC). These procedures are associated with many complications. However, very few data are available regarding the psychiatric morbidities that might occur. The present study assessed the epidemiology of depressive mood and anxiety during the 6 months following the procedure. The analysis of a prospective cohort that included patients who underwent CRS with or without HIPEC between December 2016 and December 2019 was performed...
September 7, 2023: Scientific Reports
https://read.qxmd.com/read/37673112/principles-of-surgical-management-of-peritoneal-mesothelioma
#33
REVIEW
Jessica A Steadman, Travis E Grotz
Malignant peritoneal mesothelioma (MPeM) is a rare malignancy and represents 5% to 30% of malignant mesothelioma cases. The primary curative therapy for MPeM is radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), with the strongest predictor of long-term survival being complete cytoreduction. There is a paucity of high-quality evidence available to guide management in MPeM; however, NCCN Guidelines for the management of MPeM were updated this year. In well-selected patients, 5-year overall survival exceeds 65%, but achieving optimal results requires careful preoperative evaluation and expert surgical management...
September 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/37673108/mesothelioma-peritoneal-version-2-2023-nccn-clinical-practice-guidelines-in-oncology
#34
JOURNAL ARTICLE
David S Ettinger, Douglas E Wood, James Stevenson, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Malcolm DeCamp, Thomas J Dilling, Jonathan Dowell, Gregory A Durm, Scott Gettinger, Travis E Grotz, Matthew A Gubens, Aparna Hegde, Rudy P Lackner, Michael Lanuti, Jules Lin, Billy W Loo, Christine M Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C Mullikin, Thomas Ng, Gregory A Otterson, Sandip P Patel, Tejas Patil, Patricio M Polanco, Gregory J Riely, Jonathan Riess, Theresa A Shapiro, Aditi P Singh, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C Yang, Edwin Yau, Kristina M Gregory, Miranda Hughes
Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The NCCN Guidelines for PeM provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated PeM. The diagnosis of PeM may be delayed because PeM mimics other diseases and conditions and because the disease is so rare. The pathology section was recently updated to include new information about markers used to identify mesothelioma, which is difficult to diagnose...
September 2023: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/37626251/aso-author-reflections-survivorship-in-the-balance-the-paradox-of-longevity-and-quality-of-life-in-patients-with-peritoneal-surface-malignancy
#35
JOURNAL ARTICLE
Casey J Allen
No abstract text is available yet for this article.
August 25, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/37620536/aso-author-reflections-closing-the-gap-a-call-to-action-to-improve-access-and-outcomes-of-peritoneal-surface-malignancy-care
#36
JOURNAL ARTICLE
Nolan M Winicki, Fabian M Johnston, Jonathan B Greer
No abstract text is available yet for this article.
August 24, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/37602964/annual-report-of-the-committee-on-gynecologic-oncology-the-japan-society-of-obstetrics-and-gynecology-annual-patient-report-for-2020-and-annual-treatment-report-for-2015
#37
JOURNAL ARTICLE
Kiyoshi Yoshino, Tomoko Kurita, Fumiaki Takahashi, Satoru Nagase
AIM: To provide information including the trend of gynecological malignancies in Japan, we hereby present the annual patient report for 2020 and the Annual Treatment Report for 2015, on the outcomes of patients who started treatment in 2015. METHODS: The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2020 were analyzed retrospectively...
August 21, 2023: Journal of Obstetrics and Gynaecology Research
https://read.qxmd.com/read/37596406/ascitic-autotaxin-as-a-potential-prognostic-diagnostic-and-therapeutic-target-for-epithelial-ovarian-cancer
#38
JOURNAL ARTICLE
Jung-A Choi, Hyosun Kim, Hyunja Kwon, Elizabeth Hyeji Lee, Hanbyoul Cho, Joon-Yong Chung, Jae-Hoon Kim
BACKGROUND: Malignant ascites contributes to the metastatic process by facilitating the multifocal dissemination of ovarian tumour cells onto the peritoneal surface. However, the prognostic and diagnostic relevance of ascitic fluid remains largely unknown. Herein, we investigated the potential clinical value and therapeutic utility of ascitic autotaxin (ATX) in epithelial ovarian cancer (EOC). METHODS: ATX expression was assessed in clinical samples. Spheroid-forming assay, real-time PCR, western blot analysis, invadopodia assay, and adhesion assays were performed...
August 18, 2023: British Journal of Cancer
https://read.qxmd.com/read/37569679/galectin-4-is-involved-in-the-structural-changes-of-glycosphingolipid-glycans-in-poorly-differentiated-gastric-cancer-cells-with-high-metastatic-potential
#39
JOURNAL ARTICLE
Kazuko Hachisu, Akiko Tsuchida, Yoshio Takada, Mamoru Mizuno, Hiroko Ideo
Gastric cancer with peritoneal dissemination is difficult to treat surgically, and frequently recurs and metastasizes. Currently, there is no effective treatment for this disease, and there is an urgent need to elucidate the molecular mechanisms underlying peritoneal dissemination and metastasis. Our previous study demonstrated that galectin-4 participates in the peritoneal dissemination of poorly differentiated gastric cancer cells. In this study, the glycan profiles of cell surface proteins and glycosphingolipids (GSLs) of the original (wild), galectin-4 knockout (KO), and rescue cells were investigated to understand the precise mechanisms involved in the galectin-4-mediated regulation of associated molecules, especially with respect to glycosylation...
August 1, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37535272/defining-the-values-and-quality-of-life-of-cancer-survivors-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-an-international-survey-study
#40
JOURNAL ARTICLE
Chelsea M Knotts, Mayar A Osman, Aderinsola A Aderonmu, Nathan Bahary, Patrick L Wagner, David L Bartlett, Casey J Allen
BACKGROUND: Advances in treatment of peritoneal surface malignancies including cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS±HIPEC) have led to long-term survivorship, yet the subsequent quality of life (QOL) and values of these patients are unknown. PATIENTS AND METHODS: Survivors were offered surveys via online support groups. Novel items assessed how patients prioritized experience, costs, longevity, and wellbeing. RESULTS: Of the 453 gastrointestinal/hepatobiliary (GI/HPB) surgical patients that responded, 74 underwent CRS±HIPEC and were 54±12 years old, 87% female, and 93% white...
August 3, 2023: Annals of Surgical Oncology
keyword
keyword
23975
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.